ResMed (ASX:RMD) reported Thursday fiscal third-quarter earnings of $2.37 per diluted share on a non-GAAP basis, up from $2.13 per diluted share a year earlier.
On a GAAP basis, diluted earnings per share rose to $2.58 from $2.04 year on year, the filing said.
Analysts polled by Visible Alpha were expecting EPS of $2.22.
Revenue for the three months ended March 31 was $1.29 billion, up 8% from $1.19 billion in the same period last year. Analysts surveyed by Visible Alpha expected $1.27 billion.
The board declared a quarterly dividend of $0.053 per share, up from the $0.048 in the previous reported period, payable on June 12 to shareholders on record as of May 8.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。